Alzheimer’s disease, obesity, coronary artery diseases, and stroke are not isolated, but they are deeply interconnected pathophysiological states that share overlapping etiologies, progression patterns, and therapeutic responses.
Biomed has developed Unified Acceleration Platform™, which is based on Dr. Lloyd Tran’s Unified Theory on Neurodegenerative Diseases, Metabolic Disorders, and Cardiovascular Diseases.
The Unified Theory posits that shared molecular, cellular, and systemic dysfunctions—especially in energy metabolism, chronic inflammation, and cellular senescence, neurogenesis —are central drivers of these diseases.
Biomed has developed a family of patented drugs for the treatment of ALS, Alzheimer’s disease, major depressive disorder, stroke, diabetes obesity, MASH and rare diseases including Rett Syndrome and Fragile X.
NA-704: for the treatment and prevention Amyotrophic Lateral Sclerosis (ALS)
(Phase 2B)
NA-731: for the treatment and prevention Traumatic Brain Injury (TBI)
(Phase 2A)
NA-831: for the treatment and prevention of Mild and Moderate Alzheimer’s Disease (Phase 2B/3)
NA-901: for the treatment of Major Depressive Disorder (Phase 2B/3)
NA-911: for the treatment of Stroke (Phase 2A)
NA-921 (Bionetide): for the treatment of Rett Syndrome and Fragile X (Phase 2B/3)
NA-931: for the treatment of Diabetes Obesity (Phase 2B/3)
NA-941: for the treatment of Metabolic dysfunction-associated steatohepatitis (MASH) (Phase 2A)
MICROS: MICROS Infusion System (Approved by the FDA)
For further information about our products, please contact us by completing an Online Contact Form.
Thank you.
Learn more